Today: 22 March 2026
Subscribe
Browse Category

Space Industry 5 December 2025 - 11 December 2025

AST SpaceMobile (ASTS) Stock: BlueBird 6 Countdown, Fed-Fueled Rally and the High-Risk 2026 Outlook

AST SpaceMobile (ASTS) Stock: BlueBird 6 Countdown, Fed-Fueled Rally and the High-Risk 2026 Outlook

AST SpaceMobile closed at $78.00 on December 11, 2025, after surging over 200% year-to-date and hitting an all-time high above $100 in October. The stock jumped sharply following a Federal Reserve rate cut and ahead of the BlueBird 6 satellite launch. Q3 results showed revenue of $14.7 million, missing estimates, and a loss of –$0.45 per share. The company reported $3.2 billion in liquidity after recent fundraising.
11 December 2025
···
Firefly Aerospace (FLY) Stock on December 11, 2025: Moon-Landing Hype Meets Lawsuit Reality

Firefly Aerospace (FLY) Stock on December 11, 2025: Moon-Landing Hype Meets Lawsuit Reality

Firefly Aerospace shares closed at $21.30 on December 10, up 9.46% after announcing a deal to fly Volta Space Technologies’ wireless power payload on its Blue Ghost lunar mission. The stock remains down about 56% from its $45 IPO price. Q3 revenue nearly doubled quarter-over-quarter to $30.8 million, but net losses persist. Market cap stands near $3.4 billion.
11 December 2025
··
Rocket Lab (RKLB) Stock After Hours on December 10, 2025: Neutron ‘Hungry Hippo’ Breakthrough, KAIST Launch and What to Watch Before Tomorrow’s Open

Rocket Lab (RKLB) Stock After Hours on December 10, 2025: Neutron ‘Hungry Hippo’ Breakthrough, KAIST Launch and What to Watch Before Tomorrow’s Open

Rocket Lab (NASDAQ: RKLB) closed Wednesday up 7.6% at $57.52 after announcing a fast-tracked Electron launch for Korea’s KAIST and confirming a record 19 missions for 2025. About 16.8 million shares changed hands, below the 20-day average. After-hours, the stock dipped slightly below the close. Shares have more than doubled year-to-date.
11 December 2025
···
SpaceX IPO 2026: Everything We Know Today About Elon Musk’s $1.5 Trillion Listing Plan

SpaceX IPO 2026: Everything We Know Today About Elon Musk’s $1.5 Trillion Listing Plan

SpaceX is preparing a 2026 IPO that could raise over $25 billion and value the company at up to $1.5 trillion, according to multiple reports. The listing would surpass Saudi Aramco’s 2019 record. Starlink’s rapid growth and new projects drive the valuation. SpaceX has not confirmed the IPO or filed with regulators; details remain unverified.
10 December 2025
····
AST SpaceMobile (ASTS) Soars Ahead of BlueBird 6: Latest Stock News, Analyst Forecasts and 2026 Outlook

AST SpaceMobile (ASTS) Soars Ahead of BlueBird 6: Latest Stock News, Analyst Forecasts and 2026 Outlook

AST SpaceMobile shares closed at $78.74 on December 10, up 8% and near 52-week highs ahead of the planned BlueBird 6 satellite launch on December 15. The company’s market cap ranges from $20 to $27 billion, despite trailing 12-month revenue of just $18.5 million and negative EBITDA. ASTS stock has surged over 250% in the past year.
10 December 2025
···
Rocket Lab (RKLB) Stock Today: Neutron Breakthrough, KAIST Launch and 2026 Forecasts Fuel Space Rally

Rocket Lab (RKLB) Stock Today: Neutron Breakthrough, KAIST Launch and 2026 Forecasts Fuel Space Rally

Rocket Lab shares traded near $53.86 midday Wednesday, valuing the company at about $28.8 billion after a volatile year. The firm advanced its next Electron launch for KAIST, carrying the NEONSAT-1A satellite, to no earlier than December 11 in New Zealand. This marks its 19th launch of 2025, surpassing last year’s record. Revenue for the trailing twelve months was $555 million with a net loss of $198 million.
10 December 2025
··
EchoStar (SATS) Surges on SpaceX IPO Buzz and Morgan Stanley Upgrade: Latest News, Stock Forecasts and Key Risks (December 10, 2025)

EchoStar (SATS) Surges on SpaceX IPO Buzz and Morgan Stanley Upgrade: Latest News, Stock Forecasts and Key Risks (December 10, 2025)

EchoStar shares rose about 6% to $93.54 by mid-day Wednesday, up over 300% year-to-date, after Morgan Stanley upgraded the stock and raised its price target to $110. The move follows renewed speculation about a 2026 SpaceX IPO, with EchoStar holding $11.1 billion in SpaceX stock. EchoStar’s market cap stands near $27 billion. Analyst ratings range from “Hold” to “Moderate Buy.”
10 December 2025
····
SpaceX Starlink Today: 2026 IPO Plans, India Launch Pricing and Record Rocket Cadence – December 10, 2025

SpaceX Starlink Today: 2026 IPO Plans, India Launch Pricing and Record Rocket Cadence – December 10, 2025

SpaceX is preparing a 2026 IPO that could value the company at over $1 trillion, with some reports citing a $1.5 trillion target. Starlink has launched in South Korea and is nearing rollout in India, while Namibia reviews its license. The company marked its 159th and 160th Falcon 9 launches of 2025 this week. Starlink now serves about 8 million customers in 150 countries.
10 December 2025
·
Space & Defense Stocks After the Bell: Rocket Lab Pops, Virgin Galactic Plunges, AeroVironment Misses as SpaceX IPO Buzz Builds (Dec. 9, 2025)

Space & Defense Stocks After the Bell: Rocket Lab Pops, Virgin Galactic Plunges, AeroVironment Misses as SpaceX IPO Buzz Builds (Dec. 9, 2025)

Space and defense stocks swung sharply Tuesday as the leveraged DFEN ETF fell 1.7%, while the sector digested news of a $1 trillion U.S. defense bill advancing in Congress and Germany preparing €52 billion in new contracts. BAE Systems rose 2.1% in London. SpaceX confirmed plans for a 2026 IPO that could become the largest in history.
9 December 2025
······
SpaceX IPO: 2026 Listing Plans, $1.5 Trillion Valuation Target and What It Means for Investors (December 2025 Update)

SpaceX IPO: 2026 Listing Plans, $1.5 Trillion Valuation Target and What It Means for Investors (December 2025 Update)

SpaceX is preparing for an IPO as early as mid-to-late 2026, targeting a $1.5 trillion valuation and aiming to raise over $30 billion, according to Bloomberg and Reuters reports on December 9. The listing would include the entire company, not just Starlink. Recent private share sales have valued SpaceX at up to $800 billion, though Elon Musk disputes the company is raising capital at that level. IPO timing could slip to 2027.
9 December 2025
···
AST SpaceMobile (ASTS) Stock on December 8, 2025: Reddit Mania, Institutional Money and the BlueBird 6 Launch Countdown

AST SpaceMobile (ASTS) Stock on December 8, 2025: Reddit Mania, Institutional Money and the BlueBird 6 Launch Countdown

AST SpaceMobile shares traded around $73.18 midday December 8, down 1%, after soaring over 200% year-to-date despite a 30% November drop. Volume topped 7.4 million shares. The company’s valuation and future hinge on the upcoming December 15 BlueBird 6 satellite launch and major carrier partnerships, amid rising debate over risks and premium pricing.
8 December 2025
··
EchoStar (SATS) Stock on December 8, 2025: SpaceX Windfall, AT&T Deal and What Comes Next for the High‑Flying Shares

EchoStar (SATS) Stock on December 8, 2025: SpaceX Windfall, AT&T Deal and What Comes Next for the High‑Flying Shares

EchoStar shares closed at $82 Friday after surging 10–12% on reports of a possible $800 billion SpaceX valuation. The stock has jumped over 370% in six months, hitting a 52-week high of $88. EchoStar’s rally follows multi-billion-dollar spectrum deals with AT&T and SpaceX, including a $22.65 billion sale to AT&T and a $19 billion agreement with SpaceX.
8 December 2025
····
Redwire Corporation (RDW) Stock Outlook – December 8, 2025: Can a High‑Risk Space–Defense Bet Really Double from Here?

Redwire Corporation (RDW) Stock Outlook – December 8, 2025: Can a High‑Risk Space–Defense Bet Really Double from Here?

Redwire shares closed at $6.39 on December 5, down over 75% from their 52-week high. The company faces cash burn, shareholder investigations, and reliance on delayed government contracts. Wall Street’s average 12-month price targets range from $13.25 to $14.50, implying potential upside of over 100%. The stock remains volatile, with models projecting possible short-term declines.
8 December 2025
·
SpaceX IPO, $800 Billion Valuation Rumors and Starship Pad Approval: Key SpaceX News, December 5–7, 2025

SpaceX IPO, $800 Billion Valuation Rumors and Starship Pad Approval: Key SpaceX News, December 5–7, 2025

SpaceX told investors it is targeting a late-2026 IPO, possibly valuing the company at up to $800 billion, according to Reuters. U.S. regulators approved a new Starship launch site in Florida. Starlink completed another rapid launch streak. Russian cosmonaut Oleg Artemyev was removed from a future SpaceX crew mission over an alleged security breach.
7 December 2025
·
Virgin Galactic (NYSE: SPCE) Stock Outlook: Q3 2025 Results, Cash Burn, Analyst Targets and the 2026 Spaceflight Countdown

Virgin Galactic (NYSE: SPCE) Stock Outlook: Q3 2025 Results, Cash Burn, Analyst Targets and the 2026 Spaceflight Countdown

Virgin Galactic closed at $4.31 per share on 5 December 2025, down over 30% year-on-year despite a recent rebound. The company reported a Q3 net loss of about $64 million on revenue of less than $0.4 million, with $424 million in cash and marketable securities as of 30 September. Implied volatility remains above 100% and the stock’s beta is 2.24.
7 December 2025
·
Rocket Lab (RKLB) Stock in December 2025: Neutron Delay, Record Revenue and 2026 Surge Hopes – Latest News, Forecasts & Analysis

Rocket Lab (RKLB) Stock in December 2025: Neutron Delay, Record Revenue and 2026 Surge Hopes – Latest News, Forecasts & Analysis

Rocket Lab shares climbed to nearly $49 on December 6, 2025, rebounding 20% after a steep November drop. Q3 revenue hit a record $155 million, up 48% year over year, though the company remains unprofitable. The Neutron rocket launch was delayed to 2026. Wall Street rates the stock a “Moderate Buy” with a $58 average price target.
6 December 2025
···
EchoStar (SATS) Stock Soars on SpaceX Windfall and Spectrum Deals as Shares Hit Record High – December 6, 2025

EchoStar (SATS) Stock Soars on SpaceX Windfall and Spectrum Deals as Shares Hit Record High – December 6, 2025

EchoStar shares surged 10% Friday to close near $82, hitting record highs after trading up to $88 intraday. Volume topped 19 million shares, far above average. The rally followed news that SpaceX, in which EchoStar holds a growing stake through recent spectrum deals, may be valued at $800 billion in a new share sale. EchoStar’s spectrum sales to SpaceX and AT&T have driven its market transformation.
6 December 2025
··
EchoStar Stock (SATS) Rockets on SpaceX Catalyst: Latest News, Forecasts and Analysis – December 5, 2025

EchoStar Stock (SATS) Rockets on SpaceX Catalyst: Latest News, Forecasts and Analysis – December 5, 2025

EchoStar shares surged about 10% on December 5, closing near $82–83 after hitting a 52-week high of $88 amid heavy trading. The rally followed reports that SpaceX is preparing a secondary share sale at an $800 billion valuation, sharply boosting the value of EchoStar’s SpaceX stake. Year-to-date, EchoStar stock is up over 230%. The company reported a large GAAP loss and ongoing challenges in its core business.
5 December 2025
··
SpaceX Eyes Late‑2026 IPO as Secondary Share Sale Targets Up to $800 Billion Valuation

SpaceX Eyes Late‑2026 IPO as Secondary Share Sale Targets Up to $800 Billion Valuation

SpaceX is preparing a secondary share sale that could value the company at up to $800 billion, according to reports on December 5. The company has told investors it aims for an IPO in the second half of 2026. Some sources say the valuation could end up closer to $560 billion, depending on final share pricing. At $800 billion, SpaceX would surpass OpenAI as the world’s most valuable private firm.
5 December 2025
··
1 … 6 7 8 9 10 … 13

Stock Market Today

  • AstraZeneca Share Price Falls 9% in a Month, Analysts See Upside Potential
    March 22, 2026, 2:33 PM EDT. AstraZeneca (LSE:AZN) shares slipped nearly 9% over the past month, tempering gains from a 21.8% total return over the last year. Despite this short-term price weakness, analyst sentiment remains constructive, updating the fair value estimate to £162.67 from £152.79, suggesting the stock is undervalued at its current £138.96 price. This revision reflects expectations of stronger earnings, improved margins, and a richer product mix. However, risks loom, including potential price pressure on key drugs and high research and development costs that may delay approvals. Investors are advised to consider both the opportunities and warnings before adjusting positions, also exploring other healthcare stocks for diversification.
Go toTop